

216 1 #87

PATENT 03.21.07

Attorney Docket No.: VEK-001.01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Knight, Stephen C.

Application No:

09/938,295

Filed:

August 23, 2001

For:

RECRUITING A PATIENT INTO A

CLINICAL TRIAL

Examiner: Not Yet Assigned

Art Unit:

2161

GROUP 3600

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on February 6, 2003.

Kerry N. Richard

Commissioner for Patents Washington, DC 20231

Sir:

Submitted herewith are:

- 1. Transmittal Form (1 pg.);
- 2. Information Disclosure Statement Under 37 CFR 1.97 (1 pg.);
- 3. Information Disclosure Statement By Applicant (Form 1449A) (1 pg.);
- 4. International Search Report (4 pages); -
- 5. Reference AA AE; and
- 6. Return Receipt Postcard.

RADEMARY RADEMARY

FEB 1 0 2003 Please type a plus sign (+) inside this box -

lease type a plus sign (+) inside this box —> (+)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMIT'	TAL
FORM	

(to be used for all correspondence after initial filing)

Application Numb r	09/938,295	
Filing Date	August 23/280	CEL
First Named Inventor	Knight, Stephen C.	CEIVED
Group Art Unit	2161	1 3 2003
Examiner Name	NYA GRO	IP 2000
Attorney Docket Number	VEK-001.01	חוסס יי

ENCLOSURES (check all that apply)							
Fee Transmittal F	orm	Assignment Par		After Allowance Communication to Group			
Fee Attached	l .	☐ Drawing(s)		Appeal Communication to Board of Appeals and Interferences			
Amendment / Res	sponse	Licensing-related Papers		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)			
After Final		Petition Routing Slip (PTO/SB/69) and Accompanying Petition		Proprietary Information			
Affidavits/dec	laration(s)	Petition to Conv Provisional App		Status Letter			
Extension of Time	e Request	Power of Attorney, Revocation Change of Correspondence Address		Other Enclosure(s) (please identify below):			
Express Abandonment Request		Terminal Disclaimer Request for Refund		Information Disclosure Statement Under 37 CFR 1.97; Copy of Search Report;			
Information Disclo		CD, Number of CD(s)		References AA - AE; Certificate of First Class Mailing; and Return Receipt Postcard			
Certified Copy of Document(s)	Priority	Remarks	Remarks Customer No 25181				
Response to Miss Incomplete Applic							
Response to Parts under 3 1.52 or 1.53							
	SIGNA	TURE OF APPLIC	ANT, ATTORNEY, OI	R AGENT			
Firm or Individual name	or . Kevin A. Oliver						
Signature	Signature WWW Signature						
Date	February 6, 2003	7					



PATENT Attorney Docket No.: VEK-001.01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Knight, Stephen C.

Application No: 09/938,295

Filed: August 23, 2001

For: Recruiting a Patient into a Clinical Trial

Examiner:

Art Unit:

Atton.

ARK OFFICE

Not Yet Assigned

GROUP 3600

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR 1.97**

Commissioner for Patents Washington, DC 20231

Sir:

In compliance with the requirements of 37 C.F.R. 1.56, submitted herewith on Form PTO-1449A is a list of publications identified in an International Search Report (ISR) in a counterpart PCT application; a copy of each publication is being submitted herewith. This submission is provided before a first office action on the merits.

Although we believe that we have appropriately provided for any fees due in connection with this submission, the Commissioner is authorized to credit any overpayment or charge any deficiencies to/from our Deposit Account No. 06-1448, Reference VEK-001.01.

Should there be any questions after reviewing this paper, the Examiner is invited to contact the undersigned at (617) 832-1241.

Date: February 6, 2003

Customer No: 25181 Patent Group Foley, Hoag LLP World Trade Center West 155 Seaport Boulevard Boston, MA 02210-2600 Respectfully Submitted

Reg. No. 42,049

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

FEB 1 0 2003

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

C mplete if Known						
Application Number	09/938,295					
Filing Date	August 23, 2001					
First Named Inventor	Knight, Station C. Fo					
Group Art Unit	2161					
Examiner Name	NYA UL ZOG					
Attorney Docket Number	VEK-001.01					

				FORFIG	N PATENT DOCU	MENTS		
	Foreign Patent Document			Name of Patentee	Date of Publication of	Pages, Columns, Lines,		
Examiner Initials*	Cite No. ¹	Office ³	Office ³ Number ⁴ Kind Code ⁵ (if known)		or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ₆
Rp	AA	; wo	98 39720		University of Florida	09/11/1998	!	
100	AB	₀₃ EP	0 936 566		Siemens, AG	08/18/1999		
P	AC	-·wo	98 49647		Medical Science Systems, Inc.	11/05/1998		
RP	AD	wo	01 55942		Florin, Lawrence B., et al.	08/02/2001		
		ОТ	HER PRIOR	ART N	ON PATENT LITE	RATURE DOCUME	ENTS	
Examiner Initials *	Cite	, I are now (acces) we get in a few property of whether the few property is a few property to the few property in a few						
	AE	*KING, CHESTER, ET AL., "MEDUS/A: Distributing Database Management for Medical Research" Computer Networks. Washington, September 20 - 23, 1982 Digest of Papers from Compcon. Fall, Computer Society International Conference, New York, I.E.E.E., US, vol. CONF. 25, 09-20/1982, pages 635-642.						

Examiner Signature	Ray Rat	Date Considered	O Wark 19 1001-
	Made Office		pe walle 19 ous

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OIPE CONTRACTOR OF THE PROPERTY OF THE PROPERT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Stephen Knight

Application No: 09/938,295

Filed:

August 23, 2001

For:

Recruiting a Patient into a Clinical

Trial

Examiner: To Be Assigned

Art Unit:

it: 2161

Attorney Document No. VEK-001

Ty Center 2100

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelop addressed to: Commissioner for Patents, Washington, DC 20231, on 5 June 2002:

Tess Beck

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97(b)(3) RECEIVED

JUN 2 0 2002

Commissioner for Patents Washington, DC 20231

GROUP 3600

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants and/or their agent in compliance with the requirements of 37 CFR §1.56. Copies of the documents are also submitted.

This Information Disclosure Statement is being submitted before the mailing date of a first action on the merits; therefore, no fee is due.

Applicants respectfully request that the Examiner consider the listed documents and indicate that each was considered by making appropriate notations on the attached Form 1449.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that the listed documents are material or constitute "prior art." If the Examiner applies the cited documents as prior art against any claim in the application and Applicants determine that the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of said document.

Applicants further reserve the right to take appropriate action to establish the patentability of the claims over the listed documents, should the cited documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account, No. 06-1448.

Respectfully submitted,

FOLEY HOAG LLP

Date: June 5, 2002

Scott E. Kamholz, M.D., Ph.D.

Reg. No. 48,543 Applicants' Agent

Customer No.: 25181

Patent Group Foley Hoag LLP 155 Seaport Boulevard Boston, MA 02210-2600 Voice: (617) 832-1000

Facsimile: (617) 832-7000

Form PTO-1449 LNEORMA	TIO	N DISCLOSURE CITA	TION		ocket Number (Optional) EK-001.01		Appli	ication Numb	Sheet Pa	
POILE)	IN A	N APPLICATION veral sheets if necessary)		Ap	plicant		1 09/93	18,295		
	잃				tephen Knight ing Date		Grow	n Art I Init	W J	Y
JUN 1 1 2002	_ 3			Au	igust 23, 2001		Orou,	p Air Omr ~	nnolos	\$ 200°
2	å.			<u> </u>	J.S. PATENT DOCUMENTS				SV CP.	
FARTE	<u> </u>	OCUMENT NUMBER	DATE		NAME	CLA	ss	p Art Unit	FILING O	BFE RIATEOU
RP	AA	5,991,731	11/23/9	9	Colon et al.	705		3	02/01/9	9
RP	AB	5,734,883	03/31/9	8	Umen et al.	395	5	. 601	04/27/9	
P	AC BA	US 2002/00022474 A1	01/03/0	2	Michelson et al.	705		3	08/08/0	
PP	DA	US 2001/0034631 A1	10/25/0		Kiselik	705	i	8	01/19/0)1
			F	OR	EIGN PATENT DOCUMENT					
	+-	OCIDADA PARA PARA PARA							Translati	
	1 "	OCUMENT NUMBER	DATE		COUNTRY	CLAS	SS	SUBCLASS	YES	NO
RP	AD	WO 01/55942 A1	08/02/0		PCT					
ļ		OTH	IER DOC	CUN	MENTS (Including Author, Title, Date, Pert re Agreement With Healthdemographics	inent Pages	Etc.)			
Rp	AE	•			•					
RP	AF	* Advance Paradigm Anno Information Services	unces Intera	ctive	Web Site; Features Secure, Convenient Mem	ber Access (to Pharm	acy Benefit Man	agement and	
1	AG	*Quintilės Invests In Physi -	cians' Onlin	ne, th	e Leading Online Service for Doctors	<u> </u>				-
	ΑН	Object Products, Inc. to D	emonstrate	Clini	ical Trials Patient Recruitment Solution at Hi	IMSS				
	AI	3 Keratoconus patients recr	uited via We	eb			R	ECEI\	/ED	
		American Onestani B		h *	First System to Match Cancer			JUN 2 0	2002	
	AJ	American Olicology Reso	urces Laund	aics i	rust System to Maich Cancer		\bigcirc r			
	AK	· Hospital Web Site Earns	Physician Ro	espec	t With Clinical Trials Section	******	ul	100P	JOUU	
	AL	'Internet (Clinical Trials	New Softw	vare à	Means Paperless Clinical Trials, Quicker Cur	es				
	CenterWatch Launches Service to Help Patients Access NIH Clinical Trials									
1	AN	DrugMonitor.com Launo	hes Web Si	te to	Advance Clinical Trial Participation		-	<u> </u>		
BO	drkoop.com & Quintiles Launch Service to Recruit Clinical Trial Patients on the Internet; Quintile-drkoop.com Clinical Trials Information Center Expands Awareness and Availability of Clinical Trials as a Treatment Option for Consumers; Service Harnesses Power of the Internet to Accelerate Enrollment of Qualified Patients, Increasing Speed and Efficiency of Drug Development Process; Center is First Consumer On-Line Service With Interactive Pre-Screening, Enrollment Tracking Features EXAMINER								et to	
	Repuid Ry Werk 19,1000									
EXAMINER: conformance a	EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.									

-	CLOSURE CITATION	Docket Number (Optional VEK-001.01)	Application Number 09/938,295
	PLICATION cets if necessary)	Applicant Stephen Knight		<u> </u>
		Filing Date August 23, 2001		Group Art Unit
JUN 1 1 2002 y		FOREIGN PATENT DO	CUMENTS	Pen N, V
AMERICAN AP	ica's Doctor to Begin Clinical	Trials Program		Technology Center 2100
AQ drkoo	p.com "Clinical Trials" web sit	e (17 pages)		7/00
AS Center	rwatch.com "CenterWatch Pati	ent Notification Service" web site (2 pages)	
EXAMINER Q	whe A Rote		DATE CONSIDERED Uack 19	. lloco
conformance and not cons	ation considered, whether of this idered. Include copy of this	or not citation is in conformance s form with next communicatio	with MPEP § 609; Drant to the applicant.	w line through citation if not in

RECEIVED
JUN 2 0 2002
GROUP 3600